Description: 4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany. Its product Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma, which is in clinical development stage. The company also out-licenses its products to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany.
Home Page: www.4sc.com
Fraunhoferstrasse 22
Planegg,
82152
Germany
Phone:
49 89 700 763 0
Officers
| Name | Title |
|---|---|
| Dr. Jason Loveridge B.Sc., FRSM, Ph.D. | Chairman of Management Board, CEO & MD |
| Ms. Kathleen Masch-Wiest | COO & Member of the Management Board |
| Ms. Anna Niedl Ph.D. | Corporate Communications & Investor Relations Officer |
| Dr. Susanne Danhauser-Riedl M.D. | Chief Medical Officer |
| Ms. Larissa Stuttem | Team Assistant |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 39.9577 |
| Price-to-Sales TTM: | 212.7043 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 15 |